Conditions: Chronic Kidney Disease, Stage 5
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 182
Healthy volunteers: no

Brief summary:
To compare the efficacy of Fosrenol (Lanthanum carbonate) and sevelamer hydrochloride in the reduction of serum phosphorus levels from baseline.

Detailed description:
To compare the efficacy of Fosrenol (Lanthanum carbonate) and sevelamer hydrochloride in the reduction of serum phosphorus levels from baseline.

Arms:
arm 1: Fosrenol (Lanthanum carbonate) arm 2: Sevelamer hydrochloride

Interventions: intervention 1: Fosrenol (Lanthanum Carbonate) intervention 2: Sevelamer hydrochloride
Intervention descriptions: intervention 1: The starting dose is a total daily dose of 2250mg of Fosrenol (Lanthanum carbonate) to a maximum dose of 3000mg daily. Chewable tablets will be administered orally with meals in 750mg and 1000mg strength tablets. intervention 2: The starting dose is a total daily dose of 4800mg of sevelamer hydrochloride up to a maximum of 6400 mg daily. Sevelamer hydrochloride 800mg tablets, administered orally with meals.

Protocol document: